Cases/Person-years; dose 2 within 8–89 days	Cases/Person-years; dose 3 >=8 days		Adjusted HR dose 3; >=8 days compared to dose 2 within 8–89 days	95 %LCI	95 %UCI		Relative vaccine effectiveness 3 vs 2 doses within 8–89 days of receipt	95 %LCI	95 %UCI
	All individuals	507/13032	656/82453		0.35	0.31	0.39		65.2	60.8	69.1
	By age:
	40–64 years	147/8516	210/50343		0.53	0.43	0.66		46.9	33.9	57.3
	65 + years	360/4515	446/32110		0.30	0.26	0.35		69.8	65.2	73.9
	By co-morbidity:
	None reported	243/11449	296/72263		0.30	0.25	0.36		69.7	64.0	74.6
	At least one	264/1582	360/10190		0.40	0.34	0.47		60.1	53.0	66.1
	Excluding immunocompromised:	484/12976	590/82064		0.33	0.29	0.37		67.3	63.0	71.1